Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS.
Diagnostic
Handgrip
Muscle strength
Muscular fatigue
Muscular recovery
Myalgic encephalomyelitis/chronic fatigue syndrome
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
19 04 2021
19 04 2021
Historique:
received:
25
12
2020
accepted:
01
03
2021
entrez:
20
4
2021
pubmed:
21
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating disease accompanied by muscular fatigue and pain. A functional measure to assess muscle fatigability of ME/CFS patients is, however, not established in clinical routine. The aim of this study is to evaluate by assessing repeat maximum handgrip strength (HGS), muscle fatigability as a diagnostic tool and its correlation with clinical parameters. We assessed the HGS of 105 patients with ME/CFS, 18 patients with Cancer related fatigue (CRF) and 66 healthy controls (HC) using an electric dynamometer assessing maximal (Fmax) and mean force (Fmean) of ten repetitive measurements. Results were correlated with clinical parameters, creatinine kinase (CK) and lactate dehydrogenase (LDH). Further, maximum isometric quadriceps strength measurement was conducted in eight ME/CFS patients and eight HC. ME/CFS patients have a significantly lower Fmax and Fmean HGS compared to HC (p < 0.0001). Further, Fatigue Ratio assessing decline in strength during repeat maximal HGS measurement (Fmax/Fmean) was higher (p ≤ 0.0012). The Recovery Ratio after an identical second testing 60 min later was significantly lower in ME/CFS compared to HC (Fmean2/Fmean1; p ≤ 0.0020). Lower HGS parameters correlated with severity of disease, post-exertional malaise and muscle pain and with higher CK and LDH levels after exertion. Repeat HGS assessment is a sensitive diagnostic test to assess muscular fatigue and fatigability and an objective measure to assess disease severity in ME/CFS.
Sections du résumé
BACKGROUND
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating disease accompanied by muscular fatigue and pain. A functional measure to assess muscle fatigability of ME/CFS patients is, however, not established in clinical routine. The aim of this study is to evaluate by assessing repeat maximum handgrip strength (HGS), muscle fatigability as a diagnostic tool and its correlation with clinical parameters.
METHODS
We assessed the HGS of 105 patients with ME/CFS, 18 patients with Cancer related fatigue (CRF) and 66 healthy controls (HC) using an electric dynamometer assessing maximal (Fmax) and mean force (Fmean) of ten repetitive measurements. Results were correlated with clinical parameters, creatinine kinase (CK) and lactate dehydrogenase (LDH). Further, maximum isometric quadriceps strength measurement was conducted in eight ME/CFS patients and eight HC.
RESULTS
ME/CFS patients have a significantly lower Fmax and Fmean HGS compared to HC (p < 0.0001). Further, Fatigue Ratio assessing decline in strength during repeat maximal HGS measurement (Fmax/Fmean) was higher (p ≤ 0.0012). The Recovery Ratio after an identical second testing 60 min later was significantly lower in ME/CFS compared to HC (Fmean2/Fmean1; p ≤ 0.0020). Lower HGS parameters correlated with severity of disease, post-exertional malaise and muscle pain and with higher CK and LDH levels after exertion.
CONCLUSION
Repeat HGS assessment is a sensitive diagnostic test to assess muscular fatigue and fatigability and an objective measure to assess disease severity in ME/CFS.
Identifiants
pubmed: 33874961
doi: 10.1186/s12967-021-02774-w
pii: 10.1186/s12967-021-02774-w
pmc: PMC8056497
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Références
Work. 2020;66(2):265-275
pubmed: 32568143
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):427-36
pubmed: 19505395
Biosci Rep. 2018 May 8;38(3):
pubmed: 29654166
Clin Biomech (Bristol, Avon). 2020 Mar;73:162-165
pubmed: 31986462
PLoS One. 2015 Jul 01;10(7):e0129898
pubmed: 26132314
Eur J Appl Physiol. 2014 Sep;114(9):1841-51
pubmed: 24878689
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
ESC Heart Fail. 2015 Jun;2(2):85-89
pubmed: 28834658
Diagnostics (Basel). 2019 Apr 10;9(2):
pubmed: 30974900
J Appl Physiol (1985). 2004 Mar;96(3):871-8
pubmed: 14578362
Springerplus. 2015 Sep 28;4:557
pubmed: 26435903
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
Eur J Neurol. 1999 Jan;6(1):63-9
pubmed: 10209352
Front Neurol. 2018 Nov 27;9:992
pubmed: 30538664
PLoS One. 2018 Mar 15;13(3):e0193672
pubmed: 29543914
Cytokine. 2001 Jul 21;15(2):80-6
pubmed: 11500083
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):795-807
pubmed: 19822097
J Clin Oncol. 2001 Jul 15;19(14):3385-91
pubmed: 11454886
Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):465-70
pubmed: 26147527
Disabil Rehabil. 2012;34(13):1140-7
pubmed: 22181560
J Transl Med. 2019 Mar 14;17(1):80
pubmed: 30871578
ESC Heart Fail. 2020 Jun;7(3):1064-1071
pubmed: 32154656
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
pubmed: 11124729
J Neurol Neurosurg Psychiatry. 1993 Sep;56(9):993-8
pubmed: 8410041
J Intern Med. 2010 Apr;267(4):394-401
pubmed: 20433583
Diagnostics (Basel). 2018 Sep 11;8(3):
pubmed: 30208578
Clin Physiol Funct Imaging. 2018 Jul;38(4):639-644
pubmed: 28782878
Sci Rep. 2020 Feb 7;10(1):2064
pubmed: 32034172
Mayo Clin Proc. 2012 Dec;87(12):1196-201
pubmed: 23218087
Eur J Clin Invest. 2014 Feb;44(2):153-9
pubmed: 24313704
Clin Rheumatol. 2016 Jan;35(1):191-203
pubmed: 25308475
Autoimmun Rev. 2020 Jun;19(6):102527
pubmed: 32247028
QJM. 2007 Aug;100(8):519-26
pubmed: 17617647
JCI Insight. 2016 Dec 22;1(21):e89376
pubmed: 28018972
Healthcare (Basel). 2020 Jun 13;8(2):
pubmed: 32545797